Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myelogenous leukaemia.

S J Lee1

  • 1Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. stephanie_lee@dfci.harvard.edu

British Journal of Haematology
|February 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of endoscopic reflux esophagitis among Koreans.

Journal of gastroenterology and hepatology·2001
Same author

Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2001
Same author

Capsaicin inhibits the voltage-operated calcium channels intracellularly in the antral circular myocytes of guinea-pig stomach.

Life sciences·2001
Same author

Cloning and characterization of tissue inhibitor of metalloproteinase-3 (TIMP-3) from shark, Scyliorhinus torazame.

Biochimica et biophysica acta·2001
Same author

Evidence of New States Decaying into Xi(*)(c)pi.

Physical review letters·2001
Same author

Observation of B --> phiK and B --> phiK*.

Physical review letters·2001
Same journal

The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.

British journal of haematology·2026
Same journal

Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.

British journal of haematology·2026
Same journal

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

British journal of haematology·2026
Same journal

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

British journal of haematology·2026
Same journal

Evaluating high-sensitivity troponin levels in people with sickle cell disease in the emergency department.

British journal of haematology·2026
Same journal

Methaemoglobinaemia: From pathophysiology to contemporary clinical management.

British journal of haematology·2026
See all related articles

Recent advancements in non-transplant and transplant therapies have significantly improved survival for chronic myeloid leukemia (CML) patients. Future research will likely focus on molecular understanding and novel treatment strategies for CML.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic myeloid leukemia (CML) management has seen significant progress.
  • Improvements in both non-transplant and transplant therapies have extended patient survival, especially in the chronic phase.

Purpose of the Study:

  • To review recent advancements in CML therapies.
  • To discuss future directions in CML treatment and understanding.

Main Methods:

  • Review of current non-transplant and transplant therapeutic strategies.
  • Discussion of emerging molecular insights into CML pathogenesis.
  • Anticipation of future therapeutic developments.

Main Results:

  • Non-transplant therapies are evolving with novel agents and combination treatments.

Related Experiment Videos

  • Transplant strategies are being refined to reduce toxicity and enhance immune-mediated eradication of CML.
  • Clinical and laboratory research is poised to introduce new therapies.

    • Conclusions:

    • Patient survival in CML has improved due to therapeutic advancements.
    • Future CML treatment will benefit from a deeper understanding of molecular leukaemogenesis.
    • Novel therapeutic options are expected to expand the armamentarium against CML.